血浆可溶性IL-6受体在胰腺癌碳离子放疗中的预后意义。

IF 1.6 4区医学 Q4 ONCOLOGY Anticancer research Pub Date : 2025-01-01 DOI:10.21873/anticanres.17406

Kazutaka Doi, Makoto Shinoto, Tetsuro Isozaki, Takashi Imai, Toshiki Aiba, Sumitaka Hasegawa, Tsuguhide Takeshima

{"title":"血浆可溶性IL-6受体在胰腺癌碳离子放疗中的预后意义。","authors":"Kazutaka Doi, Makoto Shinoto, Tetsuro Isozaki, Takashi Imai, Toshiki Aiba, Sumitaka Hasegawa, Tsuguhide Takeshima","doi":"10.21873/anticanres.17406","DOIUrl":null,"url":null,"abstract":"Background/aim: For patients with unresectable locally advanced pancreatic cancer (LAPC), carbon-ion radiotherapy (C-ion RT) can safely deliver higher doses than conventional photon therapy, increasing the potential for long-term survival. However, achieving meaningful improvements in survival rates requires reliable prognostic biomarkers to identify patients likely to benefit from treatment.Patients and methods: In this study, we measured plasma levels of soluble interleukin-6 receptor (sIL-6R) before C-ion RT and examined their association with the risk of distant metastasis (DM), local recurrence (LR), and overall survival (OS).Results: Results showed that patients with higher plasma sIL-6R levels had a lower risk of DM [hazard ratio (HR)=0.53; p=0.033] and improved OS (HR=0.55; p=0.037). No significant association was observed between LR and plasma sIL-6R levels (HR=1.47; p=0.273).Conclusion: These findings suggest that pretreatment plasma sIL-6R levels may serve as a prognostic marker for C-ion RT in LAPC.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 1","pages":"209-217"},"PeriodicalIF":1.6000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic Significance of Plasma Soluble IL-6 Receptor in Carbon-ion Radiotherapy for Pancreatic Cancer.\",\"authors\":\"Kazutaka Doi, Makoto Shinoto, Tetsuro Isozaki, Takashi Imai, Toshiki Aiba, Sumitaka Hasegawa, Tsuguhide Takeshima\",\"doi\":\"10.21873/anticanres.17406\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background/aim: For patients with unresectable locally advanced pancreatic cancer (LAPC), carbon-ion radiotherapy (C-ion RT) can safely deliver higher doses than conventional photon therapy, increasing the potential for long-term survival. However, achieving meaningful improvements in survival rates requires reliable prognostic biomarkers to identify patients likely to benefit from treatment.Patients and methods: In this study, we measured plasma levels of soluble interleukin-6 receptor (sIL-6R) before C-ion RT and examined their association with the risk of distant metastasis (DM), local recurrence (LR), and overall survival (OS).Results: Results showed that patients with higher plasma sIL-6R levels had a lower risk of DM [hazard ratio (HR)=0.53; p=0.033] and improved OS (HR=0.55; p=0.037). No significant association was observed between LR and plasma sIL-6R levels (HR=1.47; p=0.273).Conclusion: These findings suggest that pretreatment plasma sIL-6R levels may serve as a prognostic marker for C-ion RT in LAPC.\",\"PeriodicalId\":8072,\"journal\":{\"name\":\"Anticancer research\",\"volume\":\"45 1\",\"pages\":\"209-217\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anticancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21873/anticanres.17406\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17406","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景/目的：对于无法切除的局部晚期胰腺癌（LAPC）患者，碳离子放疗（C-ion RT）可以比传统光子治疗安全地提供更高的剂量，增加长期生存的可能性。然而，要实现有意义的生存率改善，需要可靠的预后生物标志物来识别可能从治疗中受益的患者。患者和方法：在本研究中，我们测量了c离子放疗前血浆中可溶性白细胞介素-6受体（sIL-6R）的水平，并研究了它们与远处转移（DM）、局部复发（LR）和总生存（OS）的关系。结果：结果显示血浆sIL-6R水平较高的患者发生DM的风险较低[危险比(HR)=0.53；p=0.033]和OS改善(HR=0.55；p = 0.037)。LR与血浆sIL-6R水平无显著相关性(HR=1.47；p = 0.273)。结论：这些结果提示预处理血浆sIL-6R水平可作为LAPC患者c离子RT的预后指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Prognostic Significance of Plasma Soluble IL-6 Receptor in Carbon-ion Radiotherapy for Pancreatic Cancer.

Background/aim: For patients with unresectable locally advanced pancreatic cancer (LAPC), carbon-ion radiotherapy (C-ion RT) can safely deliver higher doses than conventional photon therapy, increasing the potential for long-term survival. However, achieving meaningful improvements in survival rates requires reliable prognostic biomarkers to identify patients likely to benefit from treatment.

Patients and methods: In this study, we measured plasma levels of soluble interleukin-6 receptor (sIL-6R) before C-ion RT and examined their association with the risk of distant metastasis (DM), local recurrence (LR), and overall survival (OS).

Results: Results showed that patients with higher plasma sIL-6R levels had a lower risk of DM [hazard ratio (HR)=0.53; p=0.033] and improved OS (HR=0.55; p=0.037). No significant association was observed between LR and plasma sIL-6R levels (HR=1.47; p=0.273).

Conclusion: These findings suggest that pretreatment plasma sIL-6R levels may serve as a prognostic marker for C-ion RT in LAPC.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.